Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

This study is testing whether dapagliflozin — a medication originally developed for diabetes that also has kidney-protective effects — can improve anemia (low red blood cell levels) in people with moderate-to-severe chronic kidney disease (CKD). Anemia is a common and debilitating complication of CKD, and current treatments don't always work well. Researchers want to know if dapagliflozin can boost red blood cell production and reduce reliance on existing anemia medications. **You may be eligible if...** - You are 18 years or older - You have stage 3 or 4 chronic kidney disease - You have anemia related to CKD, with a hemoglobin level below 11.5 g/dL - You are already receiving erythropoiesis-stimulating agent (ESA) therapy to treat your anemia **You may NOT be eligible if...** - Your anemia is caused by something other than CKD (such as iron deficiency, thalassemia, or sickle cell disease) - You have had a heart attack or stroke in the past 6 months - You have active cancer or a recent cancer history - You have severe infections, diabetic coma, or are recovering from major surgery - You are pregnant or breastfeeding - You have pure red cell aplasia or severe gastrointestinal bleeding Talk to your doctor to see if this trial is right for you.